Kantirat Yaja

Dr. Kantirat Yaja

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
STSirapatsorn Tantayakhom
Sirapatsorn Tantayakhom
RIRatchanon Inpan
Ratchanon Inpan
KYKantirat Yaja
Kantirat Yaja
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
STSupanimit Teekachunhatean
Supanimit Teekachunhatean
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
Rice bran, a fiber-rich source of bioactive compounds, has gained attention for its potential health benefits, yet its effects on metabolic syndrome (MetS) remain unclear. This study aimed to evaluate the impact of rice bran consumption on anthropometric measures, blood pressure, glycemic control, and lipid profiles in individuals with MetS. A systematic search of PubMed/Medline, Scopus, Cochrane Library, and Embase was conducted up to 30 January 2025, to identify randomized controlled trials (RCTs) assessing rice bran supplementation. Twenty-six RCTs involving 1255 participants (642 in rice bran groups, 613 in controls) were included in the meta-analysis. Weighted mean differences (WMDs) with corresponding p values were calculated. Rice bran significantly reduced systolic blood pressure (WMD: −3.336 mmHg; p = 0.0006), diastolic blood pressure (WMD: −3.145 mmHg; p = 0.015), and HbA1c (WMD: −0.199%; p = 0.003). Lipid profiles improved, with reductions in total cholesterol (WMD: −13.594 mg/dL; p < 0.0001) and LDL cholesterol (WMD: −14.580 mg/dL; p < 0.0001), and an increase in HDL cholesterol (WMD: 3.074 mg/dL; p = 0.007). These findings suggest rice bran supplementation may be a promising natural dietary strategy for managing and preventing MetS.

13 July 2026 in Anatomy & Cell Biology
Verified
Journal Article
Open access
NTNapatsorn Thongdi
Napatsorn Thongdi
KYKantirat Yaja
Kantirat Yaja
NNNapatsaree Nuttapasit
Napatsaree Nuttapasit
PPPeraphan Pothacharoen
Peraphan Pothacharoen
SASirinda Aungsuchawan
Sirinda Aungsuchawan
WTWaleephan Treebupachatsakul
Waleephan Treebupachatsakul
Stem cell-based therapies have emerged as promising alternatives for disease modification and cell replacement, aiming to improve the quality of life in patients with Parkinson's disease. Human amniotic fluid mesenchymal stem cells (hAF-MSCs) represent a viable source due to their self-renewal ability, high proliferative capacity, and multipotent differentiation potential. This study aimed to evaluate the in vitro differentiation potential of hAF-MSCs into dopaminergic neurons. Flow cytometry and Alamar blue assays were employed to confirm mesenchymal stem cell characteristics. The hAF-derived cells fulfilled the established MSCs criteria, including fibroblast-like morphology, surface marker expression, and proliferative capacity. Upon induction with dopaminergic differentiation factors, the cells acquired neuron-like morphology. RT-qPCR analysis revealed significantly upregulated expression of neuronal and dopaminergic-specific genes (nestin, β-III-tubulin, and tyrosine hydroxylase), further supported by immunofluorescent staining showing the presence of neuron-related proteins. These findings demonstrate the potential of hAF-MSCs to differentiate into dopaminergic neurons and highlight their promise for future applications in regenerative medicine.